Références

Par Naoum Salamé — Dernière modification 26/01/2023 11:44

Covid-19 - Références bibliographiques

Coronavirus humains (HCOV)

A. Vabret et ali. Pathologie Biologie. Volume 57, n° 2 (mars 2009)

- Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and Deltacoronavirus.

Patrick C. Y. Woo et al. American Society for Microbiology. Journal of Virology. 2012.

Emergence du Sars-CoV-2

- A new coronavirus associated with human respiratory disease in China.

Fan Wu et al. Nature, volume 579. Published: 03 February 2020

- The major genetic risk factor for severe COVID-19 is inherited from Neanderthals

Hugo Zeberg & Svante Pääbo. Nature. Published 30 September 2020

Origine animale des coronavirus

- Zoonotic origins of human coronaviruses.

Zi-Wei Ye et al. Int. J. Biol. Sci. 2020, Vol. 16

- Retrouver les origines du SARS-CoV-2 dans les phylogénies de coronavirus.

Erwan Sallard et al. Med Sci (Paris). Volume 36, Numéro 8-9, Août–Septembre 2020

- Evidence for a mouse origin of the SARS-CoV-2 Omicron variant.

Changshuo Wei et al. MEDRXIV. Posted December 15, 2021.

- SARS-CoV-2: tracing the origin, tracking the evolution.

Konstantinos Voskarides. BMC Medical Genomics volume 15, Article number: 62 (2022)

Mutations de Sars-CoV-2

Interactions avec des récepteurs cellulaires

- Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2.

Wenfei Song et al. PLOS. August 13, 2018

- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Renhong Yan et al. Science. 2020 Mar 27.

- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Wanbo Tai et al. Cellular & Molecular Immunology (2020)

- Cell entry mechanisms of SARS-CoV-2.

Jian Shang et al. PNAS first published May 6, 2020.

- Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients.

Lili Li et al. Small methods, First published: 19 June 2021.

Variabilité génétique ACE2

- Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.

Yanan Cao et al. Cell Discovery volume 6. Published: 24 February 2020

- Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation.

Jiawei Chen et al. Preprints. Online: 12 March 2020

Réponse immune

- Individual genetic variation in immune system may affect severity of COVID-19.

Austin Nguyen et al. Journal of Virology. Posted April 15, 2020. Medrxriv.

- Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.

Xin Xu et al. Nat Med (2020). Published: 05 June 2020

- Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients.

Lili Li et al. Small methods, First published: 19 June 2021.

- Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection.

MEDRXIV. Posted May 17, 2021.

- Covid-19, un an après : persistance des anticorps protecteurs et réduction significative du risque de réinfection.

Institut Pasteur. Flash Presse.27.05.2021

Infection des jeunes enfants

- Clinical characteristics of COVID‐19 in children: Are they similar to those of SARS?

Char Leung. First published: 21 May 2020

- Clinical and Epidemiological Features of a Family Cluster of Symptomatic and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Gerhard K Wolf et al. Journal of the Pediatric Infectious Diseases Society. Published: 22 May 2020

Pistes thérapeutiques

- The promise of mRNA vaccines: a biotech and industrial perspective.

Nicholas A. C. Jackson et al. NPJ Vaccines. 2020; 5: 11. Published online 2020 Feb 4

- The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review.

C. Li et al. Eur Rev Med Pharmacol Sci. May 7, 2020

- Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination.

Ai-MingYu, Mei-JuanTu. Pharmacology & Therapeutics. Available online 14 August 2021.

Synthèses

- COVID-19: The first documented coronavirus pandemic in history.

Yen-ChinLiu et al. Biomedical Jornal. Available online 5 May 2020

- Coronavirus disease 2019: a clinical review.

Yang, C-L et al. Eur Rev Med Pharmacol Sci. May 7, 2020

Références archivées 22-01-2021

Navigation